Balkees Abderrahman is Postdoctoral Fellow, Breast Medical Oncology, University of Texas MD Anderson Cancer Center, 1500 Holcombe Blvd. Unit #1354, Houston, TX 77030, United States.
Claims of cancer drugs’ survival benefits must be accurate. To avoid fashion and fads, we must carefully examine the clinical and economic implications of newly approved cancer drugs before we seat them on the ‘breakthrough’ throne. In November 2017, the National Institute for Health and Care Excellence (NICE) approved palbociclib and ribociclib (for post-menopausal patients), for medical use in combination with an aromatase inhibitor, in women in the UK with hormone (oestrogen or prog
Digital ingestion tracking system in pills and medication adherence: future advantages and current limitationsSubscription
The US Food and Drug Administration (FDA)’s approval of the first-ever digital pill, Abilify MyCite, an aripiprazole tablet for the treatment of schizophrenia, marks the closest we have come to revolutionising the way the uptake of pills is monitored. On a global scale, the U
Breast cancer prevention trumps cureSubscription
Breast cancer is the most prevalent female cancer and is estimated to increase by 50% by 2030 compared to the incidence in 2011. The decision by the National Institute for Health and Care Excellence (NICE), the UK health technology appraiser, to recommend the use of preventive medicines, which are known to decrease the risk of developing breast cancer, is a welcome advance in public health. These medicines have been rigorously studied, and tens of thousands of women who at high risk of
Chemoprevention in British women is inadequateSubscription
Recent blog posts
Balkees Abderrahman highlights the problem of medication non-adherence in the treatment and prevention of breast cancer.